Pre-made Camrelizumab biosimilar ( Whole mAb, anti-PDCD1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-090
Anti-PDCD1 therapeutic antibody (Pre-made Camrelizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDCD1 therapeutic antibody (Pre-made Camrelizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University|
|Conditions Approved||Hodgkin's disease|
|Conditions Active||Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma|